| Execution period | 3 years (August 17, 2026 to August 16, 2029) |
|---|
BSE filing, NSE: AXISBANK. Summary written from the filing by ALFA Finder's alert engine.
Axis Bank Ltd: key numbers
- Share price
- ₹1,209.00
- Market cap
- ₹3,76,492 Cr
- Revenue (annual)
- ₹1,32,538 Cr
- Net profit (annual)
- ₹26,385 Cr
- P/E (TTM)
- 12.6×Sector 19.8×
- Promoter holding
- 7.86%-0.01% QoQ
- FII holding
- 38.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Axis Bank Ltd
All →Axis Bank Management Change
Axis Bank disclosed that Independent Director Girish Paranjpe ceased to be a director on completion of his tenure, effective close of business on 1 November 2026. No monetary value is involved in this change.
Axis Bank Employee Stock Options
Axis Bank granted 1,05,460 stock options at Rs.1,217 each under its ESOS 2000-01. Options vest over three years, exercisable within five years of vesting.
Axis Bank Legal & Regulatory
Axis Bank disclosed a SEBI censure order against subsidiary Axis Capital Limited. No investor harm or fraudulent design was involved.
Axis Bank Employee Stock Options
Axis Bank allotted 47,781 equity shares under its ESOP/RSU scheme. This allotment increases the bank's paid-up share capital.
Axis Bank Earnings Call Transcript: Key Takeaways
Axis Bank delivered robust credit growth and asset quality, though margins were optically compressed by FCNR deposit mobilization.
Axis Bank Management Change
Axis Bank has appointed Rahul Shukla as Group Head, Commercial and Bharat Banking, effective October 19, 2026. He will join the Bank's Senior Management team.
Other regulatory approval announcements
All →City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.
Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.